title: Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma.
authors.affiliation: Brigham and Women's Hospital; Massachusetts General Hospital; and Harvard Medical School, Boston, MA xcai@partners.org.
authors.forename: Xuemei
authors.initials: X
authors.lastname: Cai
authors.affiliation: Brigham and Women's Hospital; Massachusetts General Hospital; and Harvard Medical School, Boston, MA.
authors.forename: Shamik
authors.initials: S
authors.lastname: Bhattacharyya
authors.affiliation: Harvard Medical School, Boston, MA.
authors.forename: Anna
authors.initials: A
authors.lastname: Plitt
authors.affiliation: Brigham and Women's Hospital; Massachusetts General Hospital; and Harvard Medical School, Boston, MA.
authors.forename: Pooja
authors.initials: P
authors.lastname: Raibagkar
authors.affiliation: Brigham and Women's Hospital; Massachusetts General Hospital; and Harvard Medical School, Boston, MA.
authors.forename: Jamie N
authors.initials: JN
authors.lastname: LaBuzetta
authors.affiliation: Brigham and Women's Hospital; and Harvard Medical School, Boston, MA.
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Schleicher
authors.affiliation: Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA.
authors.forename: Nikhil C
authors.initials: NC
authors.lastname: Munshi
authors.affiliation: Brigham and Women's Hospital; and Harvard Medical School, Boston, MA.
authors.forename: Joshua P
authors.initials: JP
authors.lastname: Klein
mesh_terms: D000927:Anticonvulsants / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000097:blood*; D000069286:Bortezomib / Q000008:administration & dosage; D001921:Brain / Q000187:drug effects* / Q000473:pathology; D019468:Disease Management; D018450:Disease Progression; D005260:Female; D006801:Humans; D007145:Immunoglobulin kappa-Chains / Q000097:blood*; D000077287:Levetiracetam; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D009460:Neurologic Examination; D009553:Nimodipine / Q000008:administration & dosage; D018697:Nootropic Agents / Q000008:administration & dosage; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects*; D010889:Piracetam / Q000008:administration & dosage / Q000031:analogs & derivatives; D011115:Polyneuropathies / Q000209:etiology / Q000503:physiopathology; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced* / Q000150:complications / Q000517:prevention & control*; D055502:Secondary Prevention / Q000379:methods*; D012640:Seizures / Q000188:drug therapy / Q000209:etiology*
chemical_list: D000927:Anticonvulsants; D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D007145:Immunoglobulin kappa-Chains; D018697:Nootropic Agents; D009842:Oligopeptides; D000077287:Levetiracetam; D009553:Nimodipine; D000069286:Bortezomib; C524865:carfilzomib; D010889:Piracetam